PCR Machines in Colorado

C.R. Bard (now part of BD) is a diversified global medical technology company operating through multiple business segments: BD Interventional, BD Life Sciences, and BD Medical. The company manufactures and distributes an extensive portfolio of medical devices, consumables, and diagnostic solutions across vascular access, medication delivery, infection prevention, laboratory diagnostics, surgical instruments, and specialty medical equipment. Through the Medivance acquisition (2011), Bard offers the Arctic Sun™ Targeted Temperature Management system for precise patient temperature control in critical care settings. The company serves hospitals, healthcare systems, clinical laboratories, and other healthcare facilities with products spanning syringes and needles, catheters (central and peripheral), infusion systems, surgical mesh and grafts, diagnostic culture media, molecular testing systems, blood collection products, stents, and specialty equipment for urology, cardiology, gynecology, and interventional medicine. With thousands of SKUs across therapeutic areas including vascular surgery, gastrointestinal care, wound management, and microbiology solutions, Bard functions as a comprehensive B2B medical device and consumables supplier.

Biodesix is a CLIA-certified and CAP-accredited life sciences diagnostics company specializing in AI-driven, blood-based diagnostic tests for lung cancer and related respiratory diseases. Founded in 2005 and publicly traded since 2020, the company combines multi-omic approaches—including genomics, proteomics, and advanced mass spectrometry—with proprietary artificial intelligence algorithms to deliver personalized diagnostic solutions. Flagship offerings include the Nodify Lung Nodule Risk Assessment and IQLung Strategy Tests, which guide clinical decision-making for lung nodule management and non-small cell lung cancer treatment selection. Beyond clinical diagnostics, Biodesix operates a robust biopharma services division providing translational research, biomarker discovery, companion diagnostic development, and clinical trial support to leading biopharmaceutical and research institutions. The company's liquid biopsy technology platform enables non-invasive risk stratification and prognostic assessment, addressing a critical clinical need in early cancer detection and precision oncology.